Dr. Reddy’s [NYSE: RDY] Roll Out Lansoprazole DR Orally Disintegrating Tablets

Dr. Reddy’s Laboratories [NYSE: RDY] kicked off Lansoprazole DR Orally Disintegrating Tablets. India-based firm new tablets which are FDA approved are available in 15 mg and 30 mg. In the most recent 12- months period completed on December 2020, The Prevacid Brand and Generic have recorded sales of nearly $87 million MAT in the US.

Prevacid is the trademark of Takeda Pharmaceuticals USA, Inc. Dr. Reddy’s Laboratories has gained recognition as the provider of affordable and advance medication to sufferers and make their dreams of healthier lives true.

Dr. Reddy’s Laboratories [NYSE: RDY] share went up 0.85% during the trading session of Friday. In the past 52-weeks of trading, its share has experienced a change of $33.33 and $73.50 during the past 52-weeks low and high range, respectively. It has a total market capitalization of $10.52 billion at the time of writing.

Earlier, the firm has commenced the process with DCGI for EUA of Sputnik V. It is scheduled to present the safety data of Phase II and the interim data of Phase III to get the EUA. Phase III is anticipated has executed on 21st February 2021. Earlier, it has collaborated with RDIF to carry out the investigational study of Sputnik V.